1. Home
  2. JSPR vs RZLT Comparison

JSPR vs RZLT Comparison

Compare JSPR & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Jasper Therapeutics Inc.

JSPR

Jasper Therapeutics Inc.

HOLD

Current Price

$1.86

Market Cap

48.1M

Sector

Health Care

ML Signal

HOLD

Logo Rezolute Inc. (NV)

RZLT

Rezolute Inc. (NV)

HOLD

Current Price

$1.79

Market Cap

187.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JSPR
RZLT
Founded
2018
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
48.1M
187.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
JSPR
RZLT
Price
$1.86
$1.79
Analyst Decision
Buy
Strong Buy
Analyst Count
12
6
Target Price
$25.60
$12.33
AVG Volume (30 Days)
3.9M
12.5M
Earning Date
11-10-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.39
$1.07
52 Week High
$22.99
$11.46

Technical Indicators

Market Signals
Indicator
JSPR
RZLT
Relative Strength Index (RSI) 51.88 24.57
Support Level $1.61 $1.07
Resistance Level $1.93 $2.25
Average True Range (ATR) 0.22 0.60
MACD 0.03 -0.77
Stochastic Oscillator 45.15 7.13

Price Performance

Historical Comparison
JSPR
RZLT

About JSPR Jasper Therapeutics Inc.

Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.

About RZLT Rezolute Inc. (NV)

Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.

Share on Social Networks: